ATE296093T1 - Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen - Google Patents

Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen

Info

Publication number: ATE296093T1
Authority: AT; Austria
Prior art keywords: infections; occular; prevention; topical treatment; azalide antibiotics
Prior art date: 1999-03-31

Application number

AT00918382T

Other languages

English (en)

Inventor

Chandler R Dawson

Lyle M Bowman

Original Assignee

Insite Vision Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-31

Filing date

2000-03-27

Publication date

2005-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26961283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE296093(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-27 Application filed by Insite Vision Inc filed Critical Insite Vision Inc

2005-06-15 Application granted granted Critical

2005-06-15 Publication of ATE296093T1 publication Critical patent/ATE296093T1/de

Links

230000000699 topical effect Effects 0.000 title abstract 2
239000003242 anti bacterial agent Substances 0.000 title 1
229940088710 antibiotic agent Drugs 0.000 title 1
208000015181 infectious disease Diseases 0.000 title 1
230000002265 prevention Effects 0.000 title 1
230000003115 biocidal effect Effects 0.000 abstract 2
208000001860 Eye Infections Diseases 0.000 abstract 1
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 abstract 1
229960004099 azithromycin Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Ophthalmology & Optometry (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT00918382T 1999-03-31 2000-03-27 Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen ATE296093T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US28216599A	1999-03-31	1999-03-31
US09/346,923 US6239113B1 (en)	1999-03-31	1999-07-02	Topical treatment or prevention of ocular infections
PCT/US2000/007924 WO2000057866A2 (en)	1999-03-31	2000-03-27	Use of azalide antibiotics for the topical treatment or prevention of ocular infections

Publications (1)

Publication Number	Publication Date
ATE296093T1 true ATE296093T1 (de)	2005-06-15

Family

ID=26961283

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00918382T ATE296093T1 (de)	1999-03-31	2000-03-27	Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen

Country Status (15)

Country	Link
US (5)	US6239113B1 (de)
EP (2)	EP1588702A1 (de)
JP (1)	JP4904621B2 (de)
KR (1)	KR100701721B1 (de)
AT (1)	ATE296093T1 (de)
AU (1)	AU772228B2 (de)
CA (1)	CA2368637C (de)
CY (1)	CY1107259T1 (de)
DE (2)	DE1165058T1 (de)
DK (1)	DK1165058T3 (de)
ES (1)	ES2244421T3 (de)
HK (1)	HK1041642B (de)
MX (1)	MXPA01009718A (de)
PT (1)	PT1165058E (de)
WO (1)	WO2000057866A2 (de)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6045815A (en) *	1997-08-15	2000-04-04	Board Of Regents, The University Of Texas System	Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) *	1997-08-15	2005-01-18	Board Of Regents, The University Of Texas System	Topical formulations of natamycin/pimaricin
US6239113B1 (en) *	1999-03-31	2001-05-29	Insite Vision, Incorporated	Topical treatment or prevention of ocular infections
US7056893B2 (en)	1999-03-31	2006-06-06	Insite Vision, Inc.	Topical treatment for prevention of ocular infections
US6685958B2 (en) *	2001-04-25	2004-02-03	Insite Vision Incorporated	Quinolone carboxylic acid compositions and related methods of treatment
US6699492B2 (en)	1999-03-31	2004-03-02	Insite Vision Incorporated	Quinolone carboxylic acid compositions and related methods of treatment
JP3502574B2 (ja)	1999-06-29	2004-03-02	東亜薬品株式会社	眼感染症治療用眼軟膏剤
AR025976A1 (es)	1999-10-08	2002-12-26	Affinium Pharm Inc	Inhibidores de fab i.
US7141607B1 (en)	2000-03-10	2006-11-28	Insite Vision Incorporated	Methods and compositions for treating and inhibiting retinal neovascularization
US6914051B1 (en) *	2000-06-28	2005-07-05	David M Allen	Penetrating antibiotic gel for soft tissue diseases
WO2002007736A1 (en) *	2000-07-24	2002-01-31	Cadila Pharmaceuticals Limited	The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
CA2444597A1 (en) *	2001-04-06	2002-10-06	Affinium Pharmaceuticals, Inc.	Fab i inhibitors
FR2823441B1 (fr)	2001-04-12	2004-09-10	Thea Lab	Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
KR100431431B1 (ko) *	2001-04-25	2004-05-14	한미약품 주식회사	아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
JP2004529178A (ja) *	2001-05-11	2004-09-24	パシフィック・ファーマシューティカルズ・リミテッド	味遮蔽医薬組成物
HRP20040163A2 (en) *	2001-08-21	2005-02-28	Pfizer Products Inc.	Single dose azithromycin for treating respiratory infections
US6764997B2 (en) *	2001-10-18	2004-07-20	Teva Pharmaceutical Industries Ltd.	Stabilized azithromycin compositions
US20080149521A9 (en) *	2001-10-18	2008-06-26	Michael Pesachovich	Methods of stabilizing azithromycin
WO2003041500A1 (en) *	2001-11-14	2003-05-22	Board Of Regents, The University Of Texas System	Topical formulations of natamycin/pimaricin
US20050209446A1 (en) *	2002-02-26	2005-09-22	Meiji Seika Kaisha Ltd.	Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these
WO2003077952A1 (en) *	2002-03-18	2003-09-25	Novartis Ag	Topical composition comprising a cyclofructan, a carrier and a drug
US7354574B2 (en) *	2002-11-07	2008-04-08	Advanced Ocular Systems Limited	Treatment of ocular disease
CA2508792C (en)	2002-12-06	2013-02-05	Affinium Pharmaceuticals, Inc.	Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en)	2003-03-17	2004-09-30	Affinium Pharmaceuticals, Inc.	Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
US20040202687A1 (en) *	2003-04-14	2004-10-14	Babu M.K. Manoj	Ciprofloxacin formulations and methods of making and using the same
US20050085446A1 (en) *	2003-04-14	2005-04-21	Babu M.K. M.	Fluoroquinolone formulations and methods of making and using the same
US7125497B1 (en) *	2003-05-22	2006-10-24	Sandia Corporation	Reactive formulations for a neutralization of toxic industrial chemicals
US7083802B2 (en) *	2003-07-31	2006-08-01	Advanced Ocular Systems Limited	Treatment of ocular disease
JP2007505932A (ja) *	2003-09-18	2007-03-15	マクサイト，インコーポレイテッド	経強膜送達
US20050181018A1 (en) *	2003-09-19	2005-08-18	Peyman Gholam A.	Ocular drug delivery
US7083803B2 (en) *	2003-09-19	2006-08-01	Advanced Ocular Systems Limited	Ocular solutions
US7087237B2 (en) *	2003-09-19	2006-08-08	Advanced Ocular Systems Limited	Ocular solutions
US20050095205A1 (en) *	2003-10-31	2005-05-05	Ramesh Krishnamoorthy	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
CA2568914C (en) *	2004-06-04	2013-09-24	Affinium Pharmaceuticals, Inc.	Therapeutic agents, and methods of making and using the same
WO2006004085A1 (ja)	2004-07-02	2006-01-12	Wakamoto Pharmaceutical Co., Ltd.	アジスロマイシン含有水性医薬組成物及びその調製方法
US20060046970A1 (en) *	2004-08-31	2006-03-02	Insite Vision Incorporated	Topical otic compositions and methods of topical treatment of prevention of otic infections
US20080227730A1 (en) *	2005-01-14	2008-09-18	Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.	9A-Carbamoyl and Thiocarbamoyl Azalides With Antimalarial Activity
WO2006086750A1 (en) *	2005-02-09	2006-08-17	Macusight, Inc.	Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) *	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
JP2008533204A (ja) *	2005-03-21	2008-08-21	マクサイト，インコーポレイテッド	病気又は症状の治療のためのドラッグ送達システム
FR2884716B1 (fr) *	2005-04-22	2009-08-21	Thea Sa Lab	Utilisation de l'azithromycine pour la fabrication d'un medicament destine au traitement des infections oculaires
CN100393738C (zh) *	2005-07-05	2008-06-11	广州市微生物研究所	纳他霉素的提取纯化方法
PL1904056T3 (pl)	2005-07-18	2009-09-30	Minu Llc	Zastosowanie makrolidu do przywracania czucia rogówkowego
US20070014760A1 (en) *	2005-07-18	2007-01-18	Peyman Gholam A	Enhanced recovery following ocular surgery
US20070048389A1 (en) *	2005-08-26	2007-03-01	Fu-Pao Tsao	Stabilized and preserved ketotifen ophthalmic compositions
EP1973902A2 (de) *	2005-12-05	2008-10-01	Affinium Pharmaceuticals, Inc.	3-heterocyclylacrylamidverbindungen als fabi-inhibitoren und antibakterielle mittel
CN103214484B (zh)	2005-12-13	2016-07-06	因塞特控股公司	作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
WO2007074904A1 (ja) *	2005-12-28	2007-07-05	Wakamoto Pharmaceutical Co., Ltd.	水性医薬組成物
US20100130580A1 (en) *	2006-01-25	2010-05-27	Aciex Therapeutics, Inc.	Formulations and Methods for Treating Dry Eye
US8492400B2 (en)	2006-02-09	2013-07-23	Santen Pharmaceutical Co., Ltd.	Stable formulations, and methods of their preparation and use
US7767217B2 (en) *	2006-03-14	2010-08-03	Foresight Biotherapeutics	Ophthalmic compositions comprising povidone-iodine
CN101443004B (zh) *	2006-03-23	2013-03-06	参天制药株式会社	用于与血管通透性有关的疾病或病症的制剂
US7758553B2 (en) *	2006-04-03	2010-07-20	Insight Vision Incorporated	Drop dispenser for the delivery of uniform droplets of viscous liquids
US20070249546A1 (en) *	2006-04-22	2007-10-25	Sawaya Assad S	Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
EP2023721A2 (de) *	2006-06-05	2009-02-18	Auspex Pharmaceuticals Inc.	Herstellung und verwendung substituierter erythromycin-analoge
EP2687533B1 (de)	2006-07-20	2017-07-19	Debiopharm International SA	Acrylamidderivate als FAB-I-Hemmer
WO2008057364A1 (en) *	2006-11-02	2008-05-15	Riolan Technologies, Inc.	Method for treating blepharitis
WO2008085913A1 (en) *	2007-01-04	2008-07-17	Rib-X Pharmaceuticals, Inc.	Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US8263613B2 (en) *	2007-02-16	2012-09-11	Affinium Pharmaceuticals, Inc.	Salts, prodrugs and polymorphs of fab I inhibitors
US20080265343A1 (en) *	2007-04-26	2008-10-30	International Business Machines Corporation	Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
HUE029236T2 (en)	2007-06-13	2017-02-28	Incyte Holdings Corp	(R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
HRP20100699T1 (hr) *	2007-07-25	2011-01-31	Ixodes Gmbh	Topikalni antibioticki sastav za prevenciju lajmske bolesti
US7795231B2 (en)	2007-10-04	2010-09-14	Insite Vision Incorporated	Concentrated aqueous azalide formulations
EP2222299B1 (de) *	2007-11-19	2011-11-23	Bausch & Lomb Incorporated	Verwendung von levocabastin zur modulierung der erzeugung von proinflammatorischen zytokinen
EP2098219A1 (de)	2008-03-05	2009-09-09	PARI Pharma GmbH	Makrolidzusammensetzungen mit verbessertem Geschmack und verbesserter Stabilität
WO2009139924A2 (en)	2008-05-14	2009-11-19	Otonomy, Inc.	Controlled release corticosteroid compositions and methods for the treatment of otic disorders
BRPI0915143A2 (pt) *	2008-06-13	2017-03-21	Univ Case Western Reserve	métodos para tratar inflamação da córnea em um indivíduo e para inibir inflamação da córnea em um indivíduo associada com o uso de lente de contato, lente de contato, preparação oftálmica para tratar inflamação da cónea em um indivíduo, e, método para tratar ceratite infecciosa em um indivíduo
WO2010004435A2 (en) *	2008-07-09	2010-01-14	Aspreva International Ltd.	Formulations for treating eye disorders
WO2010006306A1 (en)	2008-07-10	2010-01-14	Inspire Pharmaceuticals, Inc.	Method of treating blepharitis
US8318817B2 (en)	2008-07-21	2012-11-27	Otonomy, Inc.	Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CL2009001884A1 (es) *	2008-10-02	2010-05-14	Incyte Holdings Corp	Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US20100158821A1 (en) *	2008-12-22	2010-06-24	Eastman Chemical Company	Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
WO2010085572A1 (en) *	2009-01-23	2010-07-29	Inspire Pharmaceuticals, Inc.	Method of treating dry eye disease with azithromycin
US10201548B2 (en)	2009-03-06	2019-02-12	Sun Pharma Global Fze	Methods for treating ocular inflammatory diseases
US20170128481A9 (en) *	2009-03-06	2017-05-11	Insite Vision Corporation	Ocular treatment with reduced intraocular pressure
US10980818B2 (en) *	2009-03-06	2021-04-20	Sun Pharma Global Fze	Methods for treating ocular inflammatory diseases
EP2427174A4 (de) *	2009-05-04	2014-01-15	Santen Pharmaceutical Co Ltd	Hemmer des mtor-signalwegs zur behandlung von augenleiden
US8106111B2 (en) *	2009-05-15	2012-01-31	Eastman Chemical Company	Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EP2432472B1 (de)	2009-05-22	2019-10-02	Incyte Holdings Corporation	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- oder heptannitril als jak-inhibitoren
MY156727A (en) *	2009-05-22	2016-03-15	Incyte Corp	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) *	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011049958A2 (en) *	2009-10-21	2011-04-28	Otonomy, Inc.	Modulation of gel temperature of poloxamer-containing formulations
EP2509596B1 (de)	2009-12-08	2019-08-28	Case Western Reserve University	Gamma aminosäure zur behandlung von augenerkrankungen
EP3354652B1 (de)	2010-03-10	2020-05-06	Incyte Holdings Corporation	Piperidin-4-yl azetidin-derivate als jak1-inhibitoren
US10045996B2 (en)	2010-03-17	2018-08-14	Novaliq Gmbh	Pharmaceutical composition for treatment of increased intraocular pressure
AR084691A1 (es)	2010-05-21	2013-06-05	Incyte Corp	Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
USD640554S1 (en)	2010-06-30	2011-06-28	Inspire Pharmaceuticals, Inc.	Medicine dispenser
EP2444063A1 (de)	2010-10-20	2012-04-25	Novaliq GmbH	Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
EP2462921A1 (de)	2010-11-11	2012-06-13	Novaliq GmbH	Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges
CA2818542A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2714010B1 (de)	2011-05-25	2017-03-01	Novaliq GmbH	Topische pharmazeutische zusammensetzung auf der basis von semifluorierten alkanen
DK2714008T3 (en)	2011-05-25	2017-03-13	Novaliq Gmbh	PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
MY165963A (en)	2011-06-20	2018-05-18	Incyte Holdings Corp	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US20140142055A1 (en) *	2011-06-29	2014-05-22	Insite Vision Corporation	Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
CN102352058B (zh) *	2011-08-04	2013-04-24	华南农业大学	稳定水溶性纤维素水凝胶粘度的复合添加剂及应用
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
WO2013065028A1 (en) *	2011-11-04	2013-05-10	Micro Labs Limited	Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
ES2625538T3 (es)	2012-01-23	2017-07-19	Novaliq Gmbh	Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
SMT201900411T1 (it)	2012-06-19	2019-09-09	Debiopharm Int Sa	Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
KR20140009819A (ko) *	2012-07-13	2014-01-23	주식회사유한양행	반코마이신 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
CN104619314B (zh)	2012-09-12	2017-09-22	诺瓦利克有限责任公司	包含半氟化烷烃的混合物的组合物
BR112015005008B1 (pt)	2012-09-12	2022-04-19	Novaliq Gmbh	Composições de alcano semifluorado
TWI761825B (zh)	2012-11-15	2022-04-21	美商英塞特控股公司	盧梭利替尼之緩釋性劑型
MX384910B (es)	2013-03-06	2025-03-14	Incyte Holdings Corp	Procesos e intermedios para hacer un inhibidor de jak.
KR102433489B1 (ko)	2013-03-14	2022-08-17	팬옵티카, 인크.	눈의 후안부로의 약물 전달을 위한 안구용 제제
US9044508B2 (en) *	2013-03-15	2015-06-02	Insite Vision Corporation	Concentrated aqueous azalide formulations
WO2014160579A1 (en) *	2013-03-25	2014-10-02	Insite Vision Incorporated	Combination anti-inflammatory ophthalmic compositions
CN114028560A (zh)	2013-07-23	2022-02-11	诺瓦利克有限责任公司	稳定的抗体组合物
SG11201600815WA (en)	2013-08-07	2016-03-30	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
WO2015031393A1 (en)	2013-08-27	2015-03-05	Otonomy, Inc.	Treatment of pediatric otic disorders
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
MY177504A (en)	2014-06-20	2020-09-17	Coopervision Int Ltd	Ophthalmic composition for the treatment of ocular infection
US9241971B1 (en)	2014-07-18	2016-01-26	Kurobe, Llc	Topical vancomycin formulation and methods of use
RU2580631C1 (ru) *	2015-03-19	2016-04-10	Общество с ограниченной ответственностью "Научно-внедренческий центр Агроветзащита"	Антибактериальное лекарственное средство в форме мази для лечения глазных болезней у животных
CN108348777B (zh)	2015-09-30	2020-04-28	诺瓦利克有限责任公司	半氟化化合物和其组合物
CN113662929A (zh)	2015-09-30	2021-11-19	诺瓦利克有限责任公司	用于眼部给药的半氟化化合物
RU2610408C1 (ru) *	2016-01-11	2017-02-09	Акционерное общество "Екатеринбургский центр МНТК "Микрохирургия глаза"	Способ лечения острых бактериальных послеоперационных эндофтальмитов
BR122023021456A2 (pt)	2016-02-26	2024-02-20	Debiopharm International S.A.	Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
USRE50060E1 (en)	2016-06-23	2024-07-30	Novaliq Gmbh	Topical administration method
JP7072898B2 (ja)	2016-08-16	2022-05-23	ユニバーシティオブロチェスター	ポリミキシンｂ／トリメトプリム系の治療薬を含有する医薬組成物
ES2969758T3 (es)	2016-09-22	2024-05-22	Novaliq Gmbh	Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko)	2016-09-23	2019-05-28	노바리크 게엠베하	시클로스포린을 포함하는 안과 조성물
ES2819005T3 (es)	2016-12-23	2021-04-14	Novaliq Gmbh	Composición oftálmica para el tratamiento de la enfermedad del ojo seco
AU2018216185B2 (en)	2017-02-02	2023-08-03	Mcmaster University	Bicarbonate as a potentiator for antimicrobial agents
EP3612228B1 (de)	2017-04-21	2023-08-23	Dermaliq Therapeutics, Inc.	Jodzusammensetzungen
US11278503B2 (en)	2017-05-12	2022-03-22	Novaliq Gmbh	Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
US20200147070A1 (en) *	2017-05-17	2020-05-14	Nextcea Inc.	Inducing phospholipidosis for enhancing therapeutic efficacy
WO2018215638A1 (en)	2017-05-26	2018-11-29	Novaliq Gmbh	Pharmaceutical compositions comprising azithromycin
MX2020003534A (es)	2017-09-27	2020-07-29	Novaliq Gmbh	Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh)	2017-10-04	2020-05-19	诺瓦利克有限责任公司	包含f6h8的眼用组合物
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja)	2018-01-30	2023-12-06	インサイト・コーポレイション	（１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
AU2019228119A1 (en)	2018-03-02	2020-09-10	Novaliq Gmbh	Pharmaceutical compositions comprising nebivolol
IL276888B2 (en)	2018-03-28	2024-12-01	Novaliq Gmbh	Pharmaceutical composition comprising timolol
CN113768934A (zh)	2018-03-30	2021-12-10	因赛特公司	使用jak抑制剂治疗化脓性汗腺炎
EP3784246A1 (de)	2018-04-27	2021-03-03	Novaliq GmbH	Ophthalmische zusammensetzungen mit tafluprost zur behandlung von glaukomen
EP3829640A4 (de)	2018-08-01	2022-05-25	McMaster University	Verfahren zur hemmung von mikrobenwachstum
WO2020061550A1 (en) *	2018-09-21	2020-03-26	Aufbau Medical Innovations Limited	Compositions and methods for glaucoma
CN112823020A (zh)	2018-10-12	2021-05-18	诺瓦利克有限责任公司	用于治疗干眼病的眼用组合物
EP3923907B1 (de)	2019-02-13	2024-09-25	Novaliq GmbH	Zusammensetzungen und verfahren zur behandlung von okularer neovaskularisation
FI3923914T3 (fi)	2019-02-14	2023-04-27	Debiopharm Int Sa	Afabisiiniformulaatio, menetelmä sen valmistamiseksi
AU2020259997B2 (en)	2019-04-18	2025-08-07	Azura Ophthalmics Ltd.	Compounds and methods for the treatment of ocular disorders
EP3955926A4 (de)	2019-04-18	2022-11-30	Azura Ophthalmics Ltd.	Verbindungen und zusammensetzungen zur behandlung von augenkrankheiten
JP7696697B2 (ja) *	2019-06-13	2025-06-23	千寿製薬株式会社	アジスロマイシン含有眼科用剤
MA56184A (fr)	2019-06-14	2022-04-20	Debiopharm Int Sa	Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm
AU2020340561B2 (en)	2019-09-06	2026-01-22	Novaliq Gmbh	Ophthalmic composition for the treatment of uveitis
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
US11419886B2 (en)	2020-11-23	2022-08-23	Sight Sciences, Inc.	Formulations and methods for treating conditions of the eye
US11459351B1 (en)	2021-04-05	2022-10-04	Azura Ophthalmics Ltd.	Compounds and methods for the treatment of ocular disorders
WO2024216070A1 (en)	2023-04-14	2024-10-17	University Of Rochester	Combinatorial pharmaceutical compositions for treatment of bacterial infections

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI8110592A8 (en)	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en)	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
ES8601706A1 (es)	1983-05-16	1985-11-16	Merck & Co Inc	Una composicion farmaceutica
US4551456A (en)	1983-11-14	1985-11-05	Merck & Co., Inc.	Ophthalmic use of norfloxacin and related antibiotics
US4512982A (en) *	1984-04-13	1985-04-23	Pfizer Inc.	9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
US4692454A (en)	1986-02-03	1987-09-08	Warner-Lambert Company	Opthalmic use of quinolone antibiotics
RO107257B1 (ro)	1987-07-09	1993-10-30	Pfizer	Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
KR920003601B1 (ko)	1987-09-03	1992-05-04	유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드	점안 싸이클로스포린(cyclosporin)의 조성물
US5807830A (en) *	1987-12-30	1998-09-15	Cytoven J.V.	Method for treatment of purulent inflammatory diseases
US5192535A (en)	1988-02-08	1993-03-09	Insite Vision Incorporated	Ophthalmic suspensions
US5188826A (en)	1988-02-08	1993-02-23	Insite Vision Incorporated	Topical ophthalmic suspensions
YU45590A (sh)	1990-03-07	1992-07-20	PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o.	Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
US5124154A (en) *	1990-06-12	1992-06-23	Insite Vision Incorporated	Aminosteroids for ophthalmic use
SI9011409A (en) *	1990-07-18	1995-10-31	Pliva Pharm & Chem Works	O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
US5912331A (en) *	1991-03-15	1999-06-15	Merck & Co., Inc.	Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A
US5225399A (en) *	1991-04-15	1993-07-06	The Children's Hospital Of Philadelphia	Antimicrobial amphiphilic peptides
US5239059A (en) *	1991-05-10	1993-08-24	The Children's Hospital Of Philadelphia	Ion-channel forming peptides
JP2880338B2 (ja) *	1991-10-25	1999-04-05	株式会社森組	圧搾気体による被移送物の圧送方式
ES2079994B1 (es) *	1992-10-07	1996-08-01	Cusi Lab	Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5424290A (en) *	1992-10-26	1995-06-13	Magainin Pharmaceuticals Inc.	Biologically active peptides and uses therefor
US5340572A (en)	1993-02-08	1994-08-23	Insite Vision Incorporated	Alkaline ophthalmic suspensions
US5804558A (en) *	1993-07-20	1998-09-08	University Of California	Protegrins
US5631004A (en)	1993-09-30	1997-05-20	Alcon Laboratories, Inc.	Use of sustained release antibiotic compositions in ophthalmic surgical procedures
EP0721324A1 (de) *	1993-10-01	1996-07-17	The Procter & Gamble Company	Verwendung von azithromycin zur behandlung von paradontose bei erwachsenen und topische zubereitungen für die verwendung
WO1995019180A1 (en) *	1994-01-14	1995-07-20	Xoma Corporation	Anti-gram-positive bacterial methods and materials
US5441939A (en)	1994-03-04	1995-08-15	Pfizer Inc.	3"-desmethoxy derivatives of erythromycin and azithromycin
US5610198A (en) *	1994-03-18	1997-03-11	The United States Of America As Represented By The Department Of Health And Human Services	Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
HRP940251B1 (en)	1994-04-15	1998-12-31	Stjepan Mutak	Process for the preparation of azithromycin dihydrochloride
US5605889A (en)	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
ES2079320B1 (es) *	1994-05-17	1996-10-16	Cusi Lab	Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
US6309630B1 (en)	1994-05-24	2001-10-30	Insite Vision Incorporated	Non-steroidal anti-inflammatory ophthalmic suspensions
AU4399396A (en)	1994-12-19	1996-07-10	Russinsky Limited	Compounds
US5872104A (en)	1994-12-27	1999-02-16	Oridigm Corporation	Combinations and methods for reducing antimicrobial resistance
US5747058A (en) *	1995-06-07	1998-05-05	Southern Biosystems, Inc.	High viscosity liquid controlled delivery system
DE69634277T2 (de)	1995-06-07	2006-01-05	Southern Biosystems, Inc., Birmingham	Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
US5767153A (en)	1995-06-07	1998-06-16	Insite Vision Incorporated	Sustained release emulsions
US5888973A (en) *	1996-08-09	1999-03-30	Xoma Corporation	Anti-chlamydial uses of BPI protein products
GB9621771D0 (en)	1996-10-18	1996-12-11	St George S Enterprises Ltd	Method of treatment of heart disease
US5814655A (en)	1996-11-14	1998-09-29	Insite Vision Incorporated	Non-steroidal ophthalmic mixtures
PT102006B (pt)	1997-05-19	2000-06-30	Hovione Sociedade Quimica S A	Novo processo de preparacao de azitromicina
US6265444B1 (en)	1997-05-23	2001-07-24	Insite Vision Incorporated	Ophthalmic composition
US6159458A (en)	1997-11-04	2000-12-12	Insite Vision	Sustained release ophthalmic compositions containing water soluble medicaments
ATE271390T1 (de) *	1997-12-02	2004-08-15	Pfizer Prod Inc	Verwendung von azithromycin zur topischen behandlung von augeninfektionen
US6861411B1 (en) *	1997-12-02	2005-03-01	Pfizer, Inc.	Method of treating eye infections with azithromycin
US6378526B1 (en) *	1998-08-03	2002-04-30	Insite Vision, Incorporated	Methods of ophthalmic administration
US7056893B2 (en) *	1999-03-31	2006-06-06	Insite Vision, Inc.	Topical treatment for prevention of ocular infections
US6239113B1 (en) *	1999-03-31	2001-05-29	Insite Vision, Incorporated	Topical treatment or prevention of ocular infections
IT1313610B1 (it) *	1999-08-09	2002-09-09	S I F I Societa Ind Farmaceuti	Processo per la preparazione di formulazioni acquose per uso oftalmico
WO2003011266A2 (en) *	2001-08-01	2003-02-13	Pfizer Products Inc.	Azalide antibiotic compositions

1999
- 1999-07-02 US US09/346,923 patent/US6239113B1/en not_active Expired - Lifetime
2000
- 2000-03-27 AU AU39203/00A patent/AU772228B2/en not_active Expired
- 2000-03-27 AT AT00918382T patent/ATE296093T1/de active
- 2000-03-27 DE DE1165058T patent/DE1165058T1/de active Pending
- 2000-03-27 JP JP2000607617A patent/JP4904621B2/ja not_active Expired - Lifetime
- 2000-03-27 KR KR1020017012268A patent/KR100701721B1/ko not_active Expired - Lifetime
- 2000-03-27 EP EP05011127A patent/EP1588702A1/de not_active Withdrawn
- 2000-03-27 WO PCT/US2000/007924 patent/WO2000057866A2/en not_active Ceased
- 2000-03-27 HK HK02103311.4A patent/HK1041642B/en not_active IP Right Cessation
- 2000-03-27 EP EP00918382A patent/EP1165058B1/de not_active Expired - Lifetime
- 2000-03-27 DE DE60020351T patent/DE60020351T2/de not_active Expired - Lifetime
- 2000-03-27 PT PT00918382T patent/PT1165058E/pt unknown
- 2000-03-27 CA CA2368637A patent/CA2368637C/en not_active Expired - Lifetime
- 2000-03-27 ES ES00918382T patent/ES2244421T3/es not_active Expired - Lifetime
- 2000-03-27 DK DK00918382T patent/DK1165058T3/da active
- 2000-03-27 MX MXPA01009718A patent/MXPA01009718A/es active IP Right Grant
2001
- 2001-01-24 US US09/767,943 patent/US6569443B1/en not_active Expired - Lifetime
2003
- 2003-04-07 US US10/407,425 patent/US7749970B2/en not_active Expired - Fee Related
2004
- 2004-07-26 US US10/898,170 patent/US7732415B2/en not_active Expired - Fee Related
2005
- 2005-08-24 CY CY20051101022T patent/CY1107259T1/el unknown
2007
- 2007-05-08 US US11/801,345 patent/US20080161250A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7749970B2 (en)	2010-07-06
WO2000057866A3 (en)	2001-08-16
EP1165058B1 (de)	2005-05-25
CA2368637C (en)	2011-01-18
KR20020005634A (ko)	2002-01-17
ES2244421T3 (es)	2005-12-16
PT1165058E (pt)	2005-10-31
US20040266702A1 (en)	2004-12-30
CA2368637A1 (en)	2000-10-05
DE60020351T2 (de)	2006-01-26
US20030206956A1 (en)	2003-11-06
AU772228B2 (en)	2004-04-22
JP4904621B2 (ja)	2012-03-28
JP2002540147A (ja)	2002-11-26
CY1107259T1 (el)	2012-11-21
US20080161250A1 (en)	2008-07-03
US7732415B2 (en)	2010-06-08
KR100701721B1 (ko)	2007-03-29
EP1588702A1 (de)	2005-10-26
HK1041642B (en)	2005-12-23
DE1165058T1 (de)	2002-10-02
DK1165058T3 (da)	2005-09-19
MXPA01009718A (es)	2002-08-12
WO2000057866A2 (en)	2000-10-05
AU3920300A (en)	2000-10-16
US6239113B1 (en)	2001-05-29
EP1165058A2 (de)	2002-01-02
DE60020351D1 (de)	2005-06-30
US6569443B1 (en)	2003-05-27
HK1041642A1 (en)	2002-07-19

Legal Events

Date

Code

Title

Description

2006-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1165058

Country of ref document: EP

Publication	Publication Date	Title
DE60020351D1 (de)	2005-06-30	Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen
GEP20053429B (en)	2005-01-25	3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents
MXPA02002895A (es)	2003-10-14	Tratamiento topico de infecciones por estreptococcus.
BR0210941A (pt)	2004-06-08	Terapia de combinação de oxazolidinonas substituìdas
DE60307860D1 (de)	2006-10-05	Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
AR027234A1 (es)	2003-03-19	Derivados de la toxina clostridial y metodos para el tratamiento del dolor
FR11C0037I2 (fr)	2012-06-22	Antibiotiques macrolides et traitement de la pasteurellose
BR9510423A (pt)	2003-01-07	Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
MXPA03003168A (es)	2003-07-14	Composicion antibiotica topica para el tratamiento de infeccion de los ojos.
BR9710768A (pt)	1999-08-17	Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
EA200500804A1 (ru)	2005-12-29	Топические противоинфекционные композиции
PT925789E (pt)	2004-10-29	Es oculares utilizacao de azitromicina no tratamento topico de infecco
ATE335499T1 (de)	2006-09-15	Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ES2163186T3 (es)	2002-01-16	Composicion que comprende mupirocina y clorhexidina.
PT90085A (pt)	1989-11-10	Processo para a preparacao de composicoes farmaceuticas contendo um complexo organico de ouro para aplicacao topica
BR9912004A (pt)	2001-04-10	Oxazolidinonas para tratar infecções dos olhos
BR0006301A (pt)	2001-11-27	Macrólidos antibacterianos e pró-cinéticos
ATE337002T1 (de)	2006-09-15	Topische behandlung zur vorbeugung von augeninfektionen
BR9807444A (pt)	2000-04-25	Produto antimicrobial
EA200100010A1 (ru)	2001-06-25	Местное применение оксазолидинонов для трансдермальной доставки
EP0389924A3 (de)	1991-08-14	Verwendung von Purpuromycin zur Behandlung von Vaginalinfektionen
ES2196769T3 (es)	2003-12-16	Uso topico de loperamide para el tratamiento de infecciones microbianas.
BR0014751A (pt)	2002-07-02	Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
PT852497E (pt)	2002-10-31	Utilizacao de derivados de prostano e a sua combinacao com antibioticos no tratamento de infeccoes bacterianas
BR0007491A (pt)	2001-11-20	Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções